Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNYSE:BHCNASDAQ:MIRMNASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$19.80+1.4%$21.89$13.53▼$35.25$1.54B2.021.39 million shs1.27 million shsBHCBausch Health Companies$5.41-0.6%$6.21$3.96▼$9.85$2.00B0.432.69 million shs1.64 million shsMIRMMirum Pharmaceuticals$41.31+1.3%$43.90$23.83▼$54.23$2.04B1519,571 shs307,343 shsURGNUroGen Pharma$11.26+14.1%$10.44$8.94▼$20.70$519.02M0.8526,662 shs2.32 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+1.43%+8.55%-10.85%-21.62%-7.39%BHCBausch Health Companies-0.18%+14.62%-16.58%-28.77%-37.89%MIRMMirum Pharmaceuticals+1.25%+7.61%-10.18%-14.89%+68.89%URGNUroGen Pharma+14.08%+16.56%+0.54%+4.84%-20.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.0197 of 5 stars4.51.00.00.02.42.50.6BHCBausch Health Companies4.1886 of 5 stars2.93.00.04.02.61.71.9MIRMMirum Pharmaceuticals4.2224 of 5 stars3.51.00.04.23.63.30.6URGNUroGen Pharma4.3866 of 5 stars4.52.00.04.52.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$49.45149.77% UpsideBHCBausch Health Companies 1.86Reduce$7.1732.47% UpsideMIRMMirum Pharmaceuticals 3.09Buy$58.2040.89% UpsideURGNUroGen Pharma 3.00Buy$32.86191.80% UpsideCurrent Analyst Ratings BreakdownLatest URGN, MIRM, BHC, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.004/28/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.004/17/2025URGNUroGen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$22.00 ➝ $16.004/16/2025URGNUroGen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$23.004/7/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.503/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.003/12/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/11/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $55.003/10/2025BEAMBeam TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$34.003/10/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M31.35N/AN/A$12.04 per share1.64BHCBausch Health Companies$9.63B0.21$5.76 per share0.94($0.89) per share-6.08MIRMMirum Pharmaceuticals$336.89M6.06N/AN/A$5.33 per share7.75URGNUroGen Pharma$90.40M5.74N/AN/A($2.78) per share-4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)BHCBausch Health Companies-$46M-$0.12N/A1.160.37-0.48%-577.82%5.24%4/30/2025 (Estimated)MIRMMirum Pharmaceuticals-$163.41M-$1.85N/AN/AN/A-31.69%-41.22%-14.81%5/6/2025 (Estimated)URGNUroGen Pharma-$102.24M-$3.23N/AN/AN/A-129.11%N/A-47.94%5/12/2025 (Estimated)Latest URGN, MIRM, BHC, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35N/AN/AN/AN/AN/A5/12/2025Q1 2025URGNUroGen Pharma-$0.83N/AN/AN/A$22.71 millionN/A5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11N/AN/AN/A$14.69 millionN/A4/30/2025Q1 2025BHCBausch Health Companies$1.46N/AN/AN/A$2.29 billionN/A3/10/2025Q4 2024URGNUroGen Pharma-$0.69-$0.80-$0.11-$0.80$25.25 million$24.57 million2/26/2025Q4 2024MIRMMirum Pharmaceuticals-$0.27-$0.49-$0.22-$0.49$96.64 million$99.41 million2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 million2/19/2025Q4 2024BHCBausch Health Companies$1.65$1.21-$0.44$0.25$2.51 billion$2.56 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.904.55%N/AN/A N/ABHCBausch Health CompaniesN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69BHCBausch Health CompaniesN/A0.860.62MIRMMirum Pharmaceuticals1.333.343.15URGNUroGen Pharma4.779.008.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%BHCBausch Health Companies78.65%MIRMMirum PharmaceuticalsN/AURGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics4.20%BHCBausch Health Companies8.12%MIRMMirum Pharmaceuticals22.87%URGNUroGen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableBHCBausch Health Companies19,900369.51 million338.06 millionOptionableMIRMMirum Pharmaceuticals14049.45 million37.03 millionOptionableURGNUroGen Pharma20046.09 million22.26 millionOptionableURGN, MIRM, BHC, and BEAM HeadlinesRecent News About These CompaniesUroGen Pharma announces results from Phase 1 study of UGN-301April 28 at 11:59 AM | markets.businessinsider.comAdage Capital Partners GP L.L.C. Has $31.18 Million Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)April 28 at 5:37 AM | marketbeat.comUroGen Pharma announces long-term follow up data from OPTIMA II Phase 2b studyApril 28 at 1:54 AM | markets.businessinsider.comUroGen Pharma reports long-term follow-up study with JELMYTOApril 28 at 1:54 AM | markets.businessinsider.comOLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO TreatmentApril 27 at 5:05 PM | businesswire.comNew Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBCApril 27 at 1:00 PM | businesswire.comNew Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBCApril 27 at 12:30 PM | businesswire.comUroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)April 26 at 6:30 PM | businesswire.comUroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder CancerApril 26 at 10:00 AM | businesswire.comSilverarc Capital Management LLC Buys 219,344 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)April 24, 2025 | marketbeat.com50,000 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Diadema Partners LPApril 24, 2025 | marketbeat.comThe Goldman Sachs Group Issues Pessimistic Forecast for UroGen Pharma (NASDAQ:URGN) Stock PriceApril 20, 2025 | americanbankingnews.comAlliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)April 19, 2025 | marketbeat.comScotiabank Initiates Coverage on UroGen Pharma (NASDAQ:URGN)April 18, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Urogen Pharma (URGN), Ligand Pharma (LGND)April 17, 2025 | markets.businessinsider.comUroGen Pharma initiated with an Outperform at ScotiabankApril 17, 2025 | markets.businessinsider.comScotiabank Initiates Coverage of UroGen Pharma (URGN) with Sector Outperform RecommendationApril 17, 2025 | msn.comThis UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayApril 16, 2025 | benzinga.comExodusPoint Capital Management LP Acquires New Shares in UroGen Pharma Ltd. (NASDAQ:URGN)April 15, 2025 | marketbeat.comUroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong BuyApril 12, 2025 | seekingalpha.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from AnalystsApril 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, MIRM, BHC, and BEAM Company DescriptionsBeam Therapeutics NASDAQ:BEAM$19.80 +0.28 (+1.43%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$19.65 -0.15 (-0.75%) As of 04/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Bausch Health Companies NYSE:BHC$5.41 -0.03 (-0.55%) Closing price 04/28/2025 03:59 PM EasternExtended Trading$5.38 -0.03 (-0.63%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Mirum Pharmaceuticals NASDAQ:MIRM$41.31 +0.51 (+1.25%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$40.78 -0.54 (-1.30%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.UroGen Pharma NASDAQ:URGN$11.26 +1.39 (+14.08%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$11.19 -0.07 (-0.62%) As of 04/28/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
